Editor's key points † The authors assessed factor XIII (FXIII) and fibrinogen levels among a cohort of patients undergoing elective craniotomy. † Patients with a history of coagulopathy were excluded. † FXIII levels were similar, while fibrinogen levels were lower among patients suffering a haemorrhage. † Further work is needed to determine whether lower fibrinogen levels were the cause or result of bleeding.
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Adequate haemostasis depends on complex interactions of plasmatic and cellular components of the coagulation system. In the final propagation phase of clot formation, thrombin, bound to the platelet surface, activates fibrinogen to form a haemostatic fibrin clot, which is further stabilized through cross-linking by coagulation factor XIII (FXIII). 1 2 During blood loss and concomitant fluid replacement, fibrinogen is the first coagulation factor to decrease below critical levels. 3 Decreased preoperative fibrinogen levels have been associated with an increased incidence of postoperative bleeding complications in coronary artery bypass graft surgery 4 and scoliosis surgery. 5 To date, the role of fibrinogen deficiency in postoperative neurosurgical bleeding remains unclear.
The role of FXIII in neurosurgery has been controversially described previously: one study observed FXIII deficiency and described an association with devastating haematoma formation. 6 A more recent study, however, could not reproduce this finding. 7 We hypothesized that perioperative fibrinogen and FXIII levels would differ between patients with and without severe postoperative bleeding. The aim of this study was to assess perioperative fibrinogen and FXIII levels and also their potential association with severe postoperative bleeding in patients undergoing elective intracranial surgery.
were included in this prospective observational study. Exclusion criteria were age below 18 yr, intake of platelet inhibitors or vitamin K antagonists within 7 days, intake of dabigatran within 4 days or rivaroxaban within 24 h of the procedure, and an international normalized ratio (INR) above 1.2 in patients on vitamin K antagonist therapy. Patients with pre-existing coagulation disorders were also excluded.
The study was approved by the Ethics Committee of the state of Upper Austria, Linz (EK: K911). Individual patient's consent was waived due to the observational nature of the study.
General anaesthesia was induced and maintained using a continuous infusion of propofol and remifentanil; tracheal intubation was facilitated with rocuronium. A balanced crystalloid solution (Elomel-isoton w , Fresenius Kabi, Austria) was used for fluid maintenance therapy. Additional volume therapy using a balanced colloid (Volulyte w , Fresenius Kabi, Austria) or albumin and also blood products and coagulation factor concentrates were administered at the anaesthetists' discretion. A haemoglobin concentration of 8 g dl 21 was defined as a trigger for the transfusion of packed red blood cells (PBRCs). After operation, all patients were transferred to the intensive care unit (ICU), where they were weaned from the respirator and then extubated. I.V. administered piritramid combined with paracetamol or metamizol was used for postoperative pain management. Before discharge from the ICU, all patients underwent neurological testing and cerebral computer tomography (CT) or magnetic resonance imaging (MRI) scans to screen for postoperative haematoma. The low molecular weight heparin enoxaparin was used for thromboprophylaxis in a dose of 40 mg subcutaneously once daily after postoperative bleeding was ruled out using CT or MRI. Blood samples were drawn after induction of anaesthesia ('preoperative') and after skin closure ('postoperative') from an arterial catheter. The first 3 ml was always discarded. Four millilitres were drawn into a Vacuette TM tube containing trisodium citrate 3.8% (Greiner, Kremsmü nster, Austria; 9:1, v/v) for coagulation tests and 2 ml was drawn into EDTAVacuette TM tubes (Greiner) for complete blood count. The samples were sent to the hospital's central laboratory immediately.
Serum creatinine, alanine aminotransferase, and aspartate aminotransferase were determined upon hospital admission from 4 ml of venous blood drawn into a Lithium-Heparin Vacuette TM , using a Cobas 6000 analyser (Roche, GrenzachWyhlen, Germany). Preoperative kidney function was calculated using the modified MDRD formula (reference range 0 to .60 ml min 21 ). 8 After centrifugation, prothrombin time (PT, given as per cent of normal), activated partial thromboplastin time (aPTT, given in seconds), fibrinogen level (Clauss method, mg dl 21 ), and FXIII (HEXAMATE Factor XIII, Medical & Biological Laboratories Co., Ltd, Nagano, Japan, given as per cent, reference range 65-125%) were determined using an automated coagulation analyser (STA-R Evolution w , Stago, Asnieres, France). Complete blood counts were assessed with a Sysmex XE-2100 cell counter (Sysmex, Kobe, Japan). Routine coagulation tests and complete blood counts were available to the anaesthetist within 60 min. Unless FXIII results were requested by the treating anaesthetist, citrated plasma was stored at 2808C directly after centrifugation for subsequent FXIII determination.
The following data were recorded: patient age and sex, BMI, ASA classification, duration of surgery, type of surgery, intraoperative amount of crystalloid and colloidal fluids, intraoperative fluid balance (intraoperative crystalloids and colloids minus estimated blood loss and urine output), amount of intraoperatively and postoperatively (defined as time period until discharge from the ICU) administered PBRCs, fresh-frozen plasma (FFP), and platelets and also the intraoperative administration of fibrinogen-and prothrombin complex concentrate (PCC).
The estimated perioperative blood loss (EBL) was calculated according to the formula by Gross 9 [equation (1)] and adjusted for the perioperative administration of red blood cell concentrates [AEBL; equation (2)]. Estimated perioperative blood loss
Estimated perioperative blood loss adjusted for red blood cell transfusion
where EBL is the estimated blood loss; AEBL the estimated blood loss adjusted for red blood cell transfusion; EBV the estimated blood volume: for male patients: [body weight (kg)×70]; for female patients: [body weight (kg)×65]; HKT1 the preoperative haematocrit; HKT2 the postoperative haematocrit; and RBC# the number of PBRCs.
The main outcome parameters of this study were the perioperative fibrinogen and FXIII levels in patients with and without severe postoperative bleeding within 48 h after elective intracranial surgery. Association between coagulation parameters and bleeding and the predictive power of coagulation factor levels for severe bleeding events were secondary outcome parameters.
Statistical methods
Normally distributed data are reported as mean (standard deviation, SD); non-normal data are reported as median [interquartile range (IQR)].
The Kolmogorov-Smirnov test was used to test for normal distribution. Levene's test was used to test for equality of variances. Student's t-test was used for normally distributed data. Log transformation was performed for the pre-and postoperative fibrinogen level, and pre-and postoperative platelet count to obtain normally distributed data. For non-normally distributed data, the Mann-Whitney test was used; for paired non-normally distributed data, the Wilcoxon test was used. The x 2 test was used to test for the association of sex and bleeding. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using binary logistic regression. Correlations were calculated using the Spearman correlation
Fibrinogen deficiency and bleeding post-craniotomy coefficient. Receiver operating characteristic (ROC) curves were used to calculate a fibrinogen cut-off value and the corresponding areas under the ROC curves. A significance level of P,0.05 was considered significant. Data were analysed using IBM SPSS Statistics for Mac, Version 20.0 (IBM Corp., Armonk, NY, USA).
Results
Two hundred and ninety consecutive patients were included in the study. Seven patients (2.4%) required surgical evacuation of postoperative haematoma ('haematoma group'). Patients' characteristics and perioperative variables are shown in Table 1 .
Preoperative fibrinogen levels were in the normal range and did not differ significantly between the two groups. The postoperative fibrinogen levels were significantly lower in the haematoma group compared with the non-haematoma group (P¼0.03).
A Neither preoperative nor postoperative FXIII levels differed significantly between the two groups (P¼0.42 and 0.35, respectively). FXIII levels decreased significantly during surgery by a median of 11% (IQR 18%) from baseline. The perioperative decrease in FXIII levels correlated with the estimated perioperative blood loss adjusted for red blood cell transfusion (r¼0.51, P,0.01). The perioperative decrease in FXIII levels did not correlate with the amount of intraoperative crystalloids (r¼20.12, P¼0.58) or colloids administered (r¼0.37, P,0.01).
There was no difference in platelet count, PT, and aPTT between the two groups. The platelet count decreased by an absolute median count of 13.5 g litre 21 (IQR 33) or 6.1%
(IQR 15.0%) from baseline during surgery. Fibrinogen concentrate was administered intraoperatively in 36 (12.4%) patients. Thirty-four patients in the non-bleeding group (12.0%) and two patients in the bleeding group (28.6%) received a median amount of 1 g fibrinogen (IQR 1).
PCC was administered in 137 (48.4%) patients in the nonbleeding group and in four (57.1%) patients in the bleeding group.
The amount of fibrinogen and PCC administered did not differ significantly between the two groups (P¼0.15 and 0.72, respectively).
Discussion
In this series of 290 consecutive patients undergoing elective craniotomy, postoperative fibrinogen levels were significantly lower in patients suffering from postoperative haematoma requiring surgical intervention when compared with patients without postoperative intracranial bleeding complications ( Table 2 . This lower laboratory value has previously been suggested as a risk factor for postoperative intracranial haematoma formation by Gerlach and colleagues. 6 In contrast, in another series of 84 patients undergoing both elective and non-elective intracranial surgery, no difference in fibrinogen levels between patients with and without haematoma has been reported by Idris and colleagues. 7 Interestingly, in this study, fibrinogen levels did not decrease significantly and the mean postoperative fibrinogen level in the haematoma group was as high as 282 mg dl
21
. This might be explained by the different time points of postoperative blood sampling. In contrast to our study, where postoperative blood samples were drawn at the time of skin closure, postoperative samples in the study by Idris and colleagues were collected within 24 h after operation. As reported by Lison and colleagues, 10 fibrinogen levels increase significantly within 24 h after major surgery as an acute phase response, and low fibrinogen levels at skin closure might have increased by the time of blood sampling in the study by Idris and colleagues. Decreased preoperative fibrinogen levels have also been associated with an increased incidence in postoperative bleeding complications in coronary artery bypass graft surgery 4 and scoliosis surgery. 5 In trauma patients and patients suffering from severe perioperative bleeding, recent guidelines recommend to maintain fibrinogen plasma concentrations of 150 -200 mg dl 21 . 11 12 According to our findings and the findings by Gerlach and colleagues, 6 this target might also apply for neurosurgical procedures, since six out of seven patients in the haematoma group were within the trigger range of 150 -200 mg dl 21 recommended for therapeutic fibrinogen supplementation.
In the case of our study, 112 patients out of 290 would have been candidates for fibrinogen substitution at the end of Fibrinogen deficiency and bleeding post-craniotomy surgery. Although 22 patients with a low postoperative fibrinogen level had received perioperative fibrinogen substitution, a higher dose of fibrinogen might have been required to increase the fibrinogen level above the range of 200 mg dl 21 .
As a source of fibrinogen, FFP, cryoprecipitate, and virusinactivated fibrinogen concentrate with and without relevant amounts of FXIII are available.
Content, efficacy, and safety of these products differ and their clinical effectiveness has recently been reviewed in a systematic review. 13 Fibrinogen concentrations decreased significantly during the course of surgery. This decrease in fibrinogen correlated with the intraoperative adjusted estimated blood loss. During major blood loss, fibrinogen is the first coagulation factor to decrease below critical levels. 3 Although intracranial surgery is not routinely associated with major blood loss, a perioperative decrease in haemoglobin might indicate a concomitant reduction in plasma fibrinogen levels. Although FXIII levels decreased significantly during surgery, there was no significant difference in pre-and postoperative FXIII levels between the two groups. Similar findings have been reported by Idris and colleagues 7 in 2012, who could not demonstrate a significant difference in pre-and postoperative FXIII levels in patients with and without postoperative haematoma after craniotomy. Conversely, Gerlach and colleagues 6 reported an increased risk of postoperative haematoma in patients with decreased pre-and postoperative FXIII levels. This discrepancy might be explained by different patient selection. In our study, only patients undergoing elective craniotomy were evaluated, whereas the patient population in the study by Gerlach and colleagues also includes patients with head injury, undergoing hemicraniectomy and shunting procedures. In urgent procedures such as surgery after head trauma, blood loss and concomitant fluid replacement might be higher compared with elective surgery, and thus coagulopathy including FXIII deficiency might have been more severe in this patient population. Few randomized studies on the effect of FXIII substitution on perioperative blood loss have been reported. One randomized study comparing FXIII substitution in surgical cancer patients with a dose of 30 units kg 21 body weight with placebo could show a reduction in the median blood loss [750 (400-1000) vs 1050 (700-1800) ml]. 14 Although a randomized trial in patients undergoing elective coronary artery bypass surgery comparing the administration of 125 units of FXIII, 2500 units of FXIII, or placebo did not show a difference in the need for perioperative blood transfusions, patients with an FXIII level below 70% suffered from significantly higher postoperative blood loss than those with an FXIII level above 70%.
15
The pre-and postoperative PT, aPTT, and platelet count did not differ between the two groups in the present study. Preoperative coagulation tests could not predict the risk of postoperative haematoma. This is in concordance with a recent series of 4310 patients undergoing craniotomy, 16 which showed that preoperative PT was not associated with postoperative haemorrhagic complications. The authors considered the value of unspecific PT testing as very limited. In another series of 5694 adults undergoing non-neurosurgical procedures, PT, aPTT, and platelet count were not suitable to identify patients with haemostatic disorders. 17 FXIII activity can be measured using a photometric test or a latex-enhanced immunoassay. In the study reported by Gerlach and colleagues, a photometric test was used, whereas Idris and colleagues and our study used a latex-enhanced immunoassay. The reference ranges of the photometric assay used by Gerlach (Berichrom FXIII kit, Dade Behring, Germany; reference range 70-140%) 18 and the two latex-enhanced assays used by Idris and colleagues (HemosIL w Factor XIII Antigen, Instrumentation Laboratory, Italy; reference range 70-147%) 19 Some limitations of this study have to be considered. We only used conventional laboratory tests and analyses for FXIII levels to screen for pre-and postoperative coagulation abnormalities. Functional tests such as thromboelastometry and platelet function tests could have provided additional insight into the pathogenesis of postoperative bleeding complications. Further studies are required to assess the predictive value of functional tests for postoperative complications in patients after craniotomy.
The use of hydroxyethyl starch in this study might have resulted in an overestimation of plasma fibrinogen levels. However, the maximum amount of colloids given in both groups was 500 ml and did not differ between the groups. Despite this small amount administered, a dilutional effect of perioperative fluid administration cannot be ruled out. There was no standardized trigger for the perioperative substitution of PCC and fibrinogen concentrate. However, there was no significant difference in the incidence of PCC or fibrinogen concentrate substitution between the two groups.
The observational design of this study is not suitable to elucidate whether the low postoperative fibrinogen levels were the cause or the consequence of intracerebral bleeding. However, due to the short time period between wound closure and blood sampling and the low blood loss associated with intracerebral haematoma fibrinogen levels are not expected to decrease substantially.
To overcome these limitations and to confirm the identified fibrinogen threshold as potentially predictive for postoperative intracranial bleeding, further randomized controlled clinical trials are warranted. According to our results and the low incidence of postoperative bleeding events after neurosurgery, a sample size of 9295 patients would be required in order to detect a reduction in the incidence of postoperative haematomas by 33% (a¼0.05, b¼80%).
In conclusion, this study emphasizes the role of fibrinogen in perioperative haemostasis in intracranial surgery. Low perioperative fibrinogen levels, although within the normal reference range, were associated with an increased risk of postoperative bleeding complications. Future randomized controlled trials will be essential to confirm the proposed fibrinogen threshold and to identify patients who might benefit from fibrinogen substitution during neurosurgical procedures.
